Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Camurus AB's gross profit for the
three
months ended in Jun. 2026 was $69.1 Mil. Camurus AB's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was $224.7 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Camurus AB's gross profit for the
three
months ended in Jun. 2026 was $69.1 Mil. Camurus AB's Revenue for the
three
months ended in Jun. 2026 was $73.8 Mil. Therefore, Camurus AB's Gross Margin % for the quarter that ended in Jun. 2026 was 93.71%.
Camurus AB had a gross margin of 93.71% for the quarter that ended in Jun. 2026 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Camurus AB was 98.12%. The lowest was 77.95%. And the median was 91.19%.
Camurus AB (OTCPK:CAMRF) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Camurus AB had a gross margin of 93.71% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Camurus AB Gross Profit Related Terms
Camurus AB Gross Profit Historical Data
* Premium members only.
The historical data trend for Camurus AB's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMRF vs VRTX, REGN, ALNY: Gross Profit Comparison
For the Biotechnology subindustry, Camurus AB's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Gross Profit distribution charts can be found below:
* The bar in red indicates where Camurus AB's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $224.7 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Camurus AB (CAMRF) has a Gross Profit of $224.7 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Camurus AB and its competitors.
Is Camurus AB's Gross Profit too high?
Camurus AB's current Gross Profit is $224.7 Mil. Overall, Camurus AB has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Gross Profit compare to VRTX and REGN?
Camurus AB's Gross Profit of $224.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Camurus AB and its competitors. Camurus AB's current Gross Profit is $224.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Fairly Valued. The stock's GF Value™ is $64.08, compared to a current price of $58.51 — trading 8.7% below its estimated fair value. The current Gross Profit is $224.7 Mil. Camurus AB's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Gross Profit is $224.7 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $58.51 is trading 8.7% below its estimated GF Value™ of $64.08.
GuruFocus considers Camurus AB to be Fairly Valued.
Key valuation signals for CAMRF:
Gross Profit: $224.7 Mil
GF Value™: $64.08 vs. price of $58.51 (8.7% below fair value)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
81GF Score
Get the complete analysis for CAMRF
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
